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Abstract
Introduction Since current treatment options for patients
suffering from active rheumatoid arthritis (RA) remain
inadequate, especially for those unresponsive to disease-
modifying antirheumatic drugs (DMARDs), new and improved
medication is needed. This study evaluates the safety and
efficacy of masitinib (AB1010), a potent and selective protein
tyrosine kinase inhibitor of c-KIT, in the monotherapy treatment
of DMARD-refractory RA.
Methods This was a multicentre, uncontrolled, open-label,
randomised, dose-ranging, phase 2a trial. Masitinib was
administered orally to 43 patients who had inadequate response
to DMARDs, at initial randomised dosing levels of 3 and 6 mg/
kg per day over a 12-week period. Dose adjustment was
permitted based upon tolerability and response criteria. Efficacy
was assessed via American College of Rheumatology 20%/
50%/70% improvement criteria (ACR20/50/70) responses,
disease activity score using 28 joint counts (DAS28), index of
improvement in RA (ACRn) and C-reactive protein (CRP)
improvement, relative to baseline at week 12.
Results Improvement was observed in all efficacy endpoints,
including ACR20/50/70 scores of 54%, 26% and 8%,
respectively, and a reduction in CRP level by greater than 50%
for approximately half the population. This improvement was
sustainable throughout an extension phase (> 84 weeks) and
was also independent of initial DMARD resistance (anti-tumour
necrosis factor-alpha and/or methotrexate). A relatively high
patient withdrawal rate (37%) required the use of last
observation carried forward (LOCF) data imputation. Incidence
of adverse events was high (95%), although the majority were of
mild or moderate severity with a considerable decline in
frequency observed after 12 weeks of treatment. Two nonfatal
serious adverse events were reported. Dose-response analyses
tentatively indicate that an initial dosing level of 6.0 mg/kg per
day administered orally in two daily intakes is the most
appropriate, based upon potency and tolerability trends.
Conclusions Treatment with masitinib improved DMARD-
refractory active RA. Following an initial high incidence of mostly
mild to moderate side effects during the first 12 weeks of
treatment, masitinib appears to be generally well tolerated. This,
ABL: Abelson kinase; ACR: American College of Rheumatology; ACR20/50/70/90: American College of Rheumatology 20%/50%/70%/90% 
improvement criteria; ACRn: index of improvement in rheumatoid arthritis; AE: adverse event; anti-TNFα: anti-tumour necrosis factor-alpha; CRP: C-
reactive protein; DAS28: disease activity score using 28 joint counts; DMARD: disease-modifying antirheumatic drug; IC50: half inhibitory concentra-
tion; IL1: interleukin-1; IL1-Ra: (recombinant) interleukin-1 receptor antagonist; ITT: intention-to-treat; LOCF: last observation carried forward; MC: 
mast cell; MTX: methotrexate; NSAID: nonsteroidal anti-inflammatory drug; OC: observed case; PDGFR: platelet-derived growth factor receptor; PP: 
per protocol; RA: rheumatoid arthritis; SAE: serious adverse event; SCF: stem cell factor; TK: tyrosine kinase.Arthritis Research & Therapy    Vol 11 No 3    Tebib et al.
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together with evidence of a sustainable efficacy response,
suggests that masitinib is suitable for long-term treatment
regimens. Since this was the first study of masitinib in a
nononcologic pathology, the relatively high patient withdrawal
rate observed can be partly attributed to a highly cautious
response to adverse events. There is sufficient compelling
evidence to warrant further placebo-controlled investigation.
Trial registration ClinicalTrials.gov NCT00831922.
Introduction
Rheumatoid arthritis (RA) has a complex aetiopathogenesis
necessitating that a patient's treatment be individually and
continually tailored for effective management. Disease-modify-
ing antirheumatic drugs (DMARDs), especially methotrexate
(MTX), have become the cornerstone of RA treatment. A short-
coming of MTX, however, is that it is relatively ineffective at
inducing remission, with disease progression continuing una-
bated in many patients [1,2]. A problem more general to
DMARDs is that of drug resistance, which represents a major
obstacle to the effective long-term management of RA [3].
Both MTX [4] and anti-tumour necrosis factor-alpha (anti-
TNFα) [5] may become inefficient for controlling disease activ-
ity in severe RA. Thus, beyond the already developed biologi-
cal strategies, there exists an imperative need to identify
alternative RA treatments that demonstrate high efficacy over
time in monotherapy, exploit novel therapeutic targets for more
effective combination therapies, minimise toxicity and are
affordable. One such approach involves blocking intracellular
proinflammatory messages, which is currently represented by
the strategy of selective protein tyrosine kinase (TK) inhibition.
There is a growing body of evidence implicating mast cells
(MCs) as major contributors to the pathogenesis of RA. MCs
may be considered the immunological sentinel of the syn-
ovium, acting immediately in the event of joint trauma by liber-
ating an array of proinflammatory mediators. However, MCs
also appear to perpetuate the chronic process by their marked
increased accumulation in the synovial lining of the inflamed
joint and their ability to produce numerous proinflammatory
cytokines and growth and angiogenic factors. Some of the
most compelling evidence for the connection of MCs to RA
comes from studies in the K/BxN murine model, an animal
model of autoantibody-induced arthritis, which has demon-
strated that MC-deficient mice are resistant to arthritis, with
susceptibility restored following MC engraftment [6]. This
model has also been used to show how MCs contribute to the
initiation of joint inflammation by elaboration of interleukin-1
(IL1) [7]. As such, MCs represent an attractive therapeutic tar-
get [8-13]. Stem cell factor (SCF), the ligand of the c-KIT
receptor, is a critical growth factor for MCs and is essential to
their survival, proliferation, differentiation, adhesion and
degranulation processes [14]. Thus, there exists a strong rela-
tion between the SCF/MC c-KIT pathway and the pathogene-
sis of RA. It is hypothesised that, if this link were disrupted
through the inhibitory action of c-KIT TK activity, then inflam-
matory diseases such as RA could be controlled; that is, MCs
are strongly implicated in RA pathogenesis, SCF is closely
associated with MCs, and c-KIT is intrinsically linked with
SCF; hence, inhibition of the c-KIT pathway affects RA. Small
molecules capable of blocking ATP binding and TK activity of
c-KIT, both selectively and with a good safety profile, could
therefore represent a new class of drugs effective in RA.
Masitinib (AB1010), the investigatory drug of this study, is a
good candidate, being an ATP-binding site competitor that
acts potently and selectively by inhibiting wild-type forms of c-
KIT. In vitro masitinib has shown greater affinity and selectivity
for human and murine c-KIT receptor (wild-type: half inhibitory
concentration [IC50] of 150 nM; juxtamembrane mutation: IC50
of 5 nM; P Dubreuil, S Letard, MA Ciufolini, L Gros, PS Lev-
enthal, M Humbert, N Castéran, L Borge, B Hajem, A Lermet,
W Sippl, E Voisset, M Arock, C Auclair, PS Leventhal, CD
Mansfield, A Moussy & O Hermine, manuscript submitted) as
compared with imatinib mesylate (Gleevec, STI571; Novartis,
Basel, Switzerland), the forerunner of such therapeutic agents.
Masitinib also potently inhibits platelet-derived growth factor
receptor-alpha (PDGFRα), PDGFRβ, Lyn and (to a lesser
extent) fibroblast growth factor receptor 3 (FGFR3) and the
focal adhesion kinase (FAK) activation pathway without inhib-
iting kinases of known toxicities (P. Dubreuil and colleagues,
manuscript submitted). The maximal tolerated dose of masit-
inib has not been reached thus far in phase 1 studies of
healthy volunteers or in cancer patients who were orally admin-
istered up to 1,000 mg/day (corresponding to a weight-
adjusted dose of not more than 20 mg/kg per day for patients
weighing at least 50 kg; JC Soria, C Massard, N Magné, CD
Mansfield, T Bader, A Moussy, O Hermine & JP Armand, man-
uscript in preparation). However, it was observed that doses
of higher than 12 mg/kg per day lead to gastrointestinal disor-
ders that are probably not compatible with a long-term admin-
istration of masitinib. Dose levels of 7.5 mg/kg per day have
shown no significant toxicity, with plasmatic concentrations of
masitinib base detected at levels above the IC50 for c-KIT and
PDGFR (J.C. Soria and colleagues, manuscript in prepara-
tion). The purpose of this current study was to evaluate the
safety and efficacy of masitinib in the treatment of DMARD-
refractory active RA.
Materials and methods
Patients
Patients from 18 to 75 years of age who had been diagnosed
with active RA, according to the American College of Rheuma-
tology (ACR) criteria [15], for whom disease onset had
occurred after 16 years of age and who had a history of
DMARD failure (predominantly MTX and/or anti-TNFα) or pri-Available online http://arthritis-research.com/content/11/3/R95
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mary resistance to anti-TNFα were eligible to participate. Their
active RA had an ACR functional class of 1 to 3 [16] and a
duration of at least 6 months. In addition, patients exhibited at
least 8/66 swollen joints, at least 10/68 painful joints and at
least one of the following three conditions: erythrocyte sedi-
mentation rate of at least 28 mm/hour, C-reactive protein
(CRP) of at least 15 mg/litre or morning stiffness for at least
45 minutes at both screening and baseline time points. The
main exclusion criteria were patients with inadequate bone
marrow function (defined as an absolute neutrophil count of
not more than 2.5 × 109/litre) and a platelet count of not more
than 100 × 109/litre, active current infection, history of infec-
tion requiring hospitalisation, history of recurrent infections or
treatment with antibiotics within 2 weeks of screening. Treat-
ment washout or exclusion periods observed prior to entry to
the study were (a) DMARD use within 4 weeks, (b) five half-
lives or washout in accordance with a specific drug (whichever
is longer) (c) any live (attenuated) vaccines taken within 4
weeks, (d) use of more than one nonsteroidal anti-inflamma-
tory drug (NSAID) or change of its dosage within 4 weeks, (e)
dosage of prednisone or equivalent corticosteroid of greater
than 10 mg/day or any dosage change within 4 weeks, and (f)
dosage of prednisone or equivalent corticosteroid of greater
than 20 mg administered via intra-articular injection or bolus
intramuscular or intravenous treatment within 4 weeks. Other
exclusion criteria included any previous use of recombinant
IL1 receptor antagonist (IL1-Ra) and patients who were preg-
nant or nursing.
Study design and drug product
This was a multicentre, prospective, uncontrolled, open-label,
randomised, dose-ranging, phase 2a study of masitinib in
adults with active RA, who were followed over the course of a
12-week period. The study was approved by the local ethics
committees and was carried out in compliance with the Dec-
laration of Helsinki and good clinical practices guidelines.
Written informed consent was obtained from all patients. The
study was registered in ClinicalTrials.gov under the trial regis-
tration number NCT00831922.
Masitinib, supplied as 100 and 200 mg tablets (AB Science,
Paris, France), was administered orally in two daily intakes. To
evaluate the dose response of masitinib in DMARD-refractory
active RA, dose ranging was performed by randomly assigning
patients to one of two initial treatment groups of 3 and 6 mg/
kg per day (1:1 ratio). Dosage could be increased by 1.5 mg/
kg per day at weeks 4 and 8 in the event of insufficient
response accompanied by minimal toxicity. Likewise, the dose
could be reduced by 1.5 mg/kg per day or treatment discon-
tinued in case of serious adverse events (SAEs). Patients
exhibiting a significant improvement after 12 weeks of treat-
ment were eligible to continue receiving treatment after enter-
ing a compassionate program, wherein assessments were
performed every 4 weeks for the first 3 months of extension
and every 12 weeks thereafter.
Permitted medications for the treatment of possible cutaneous
rash and face oedema during the study were hydroxyzine
(Atarax) and prednisolone. Other permitted concomitant med-
ications were one NSAID (including cyclooxygenase 2 [COX-
2] inhibitors) at constant dosage, oral corticosteroids at stable
doses of not more than 10 mg/day, analgesics without anti-
inflammatory action or oral narcotic analgesics and medically
acceptable forms of birth control. Physical therapy, if per-
formed at the time of study entry, was provided under a stable
and consistent regimen. The following treatments of active RA
were prohibited during the study: surgery, DMARD treatment
(including MTX, anti-TNFα biology therapies, leflunomide, IL1-
Ra, azathioprine and cyclosporine), immunosuppressive
drugs, cytotoxic drugs, intramuscular or intravenous injections
of steroids, intra-articular or soft tissue injections of corticos-
teroids and alternate investigational drugs or investigational
combinations of approved drugs. Drugs that interact with the
same CYP450 isoenzymes (2C9, 2D6 and 3A4) as masitinib
were prohibited (for example, acetaminophen) due to the
inherent risk of either reduced activity or enhanced toxicity of
any concomitant medication. Finally, the use of analgesics was
prohibited on assessment days until after all clinical efficacy
evaluations had been completed.
Safety and efficacy assessment
Safety was assessed by occurrence of adverse events (AEs)
and SAEs and monitoring biochemical, haematological and
urinalysis parameters during the study period, with toxicity
graded according to the Common Toxicity Criteria version 3.0.
In the event of SAE (that is, grade 3 or 4), treatment was inter-
rupted until resolution and then resumed, with a permitted
dose reduction of 1.5 mg/kg per day or treatment discontinu-
ation if toxicity recurred. Evaluation of treatment efficacy was
based upon the evolution of clinical symptoms associated with
active RA at week 12 relative to baseline. Primary endpoints
were the ACR response criteria of ACR20, ACR50 and
ACR70 [17]. For each patient, all efficacy parameters were
recorded on the first day of treatment (baseline), prior to
administration of masitinib and then again after 4, 8 and 12
weeks of treatment. Secondary endpoints included the 12-
week analysis of disease activity score using 28 joint counts
(DAS28) [18], index of improvement in RA (ACRn) [19] and
CRP improvement. Higher DAS28 values are indicative of
greater disease activity with significance placed on the thresh-
old values of DAS28 < 2.6, 2.6 ≤ DAS28 ≤ 3.2, 3.2 < DAS28
≤ 5.1, and DAS28 > 5.1, corresponding to the classifications
of remission, inactive RA, moderate RA and very active RA,
respectively. CRP is an acute-phase reactant and a sensitive
serum marker of inflammation. Discrimination between dose
regimens was investigated by analysis of the time (days) to
first ACR variable response according to initial dosage. Since
dose adjustment was permitted at weeks 4 and 8 in cases of
insufficient treatment response, the dose at the time of first
response was also analysed.Arthritis Research & Therapy    Vol 11 No 3    Tebib et al.
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Statistical methods
Efficacy data are presented using descriptive statistics, con-
trasting initial dosage groups or according to previous
DMARD failure. For comparison of groups according to initial
dosage on a continuous variable, the Student test (with Sat-
terwhaite correction for unequal variance) or the Wilcoxon test
was used when normality was not rejected or was rejected,
respectively (normality determined via the Shapiro-Wilk test).
For the same comparison on a qualitative variable, the chi-
square or Fisher exact test (if the chi-square hypotheses were
not fulfilled) was used. The rates of patients achieving the var-
ious ACR response variables after 12 weeks of treatment
(remission rate) are presented in terms of number and percent-
age of patients. Patients were assigned to either 3 or 6 mg/kg
per day treatment groups based upon a randomisation sched-
ule generated for packaging and labelling by the Biostatistics
Section of AB Science. Individual treatment doses to be
administered were supplied in sealed envelopes to be opened
by the investigator at the time of inclusion. Patients received
the treatment from the investigator on an open basis.
Due to the relatively high patient dropout rate of this study,
analysis was conducted on two different datasets: one with an
imputation of missing values according to the last observation
carried forward (LOCF) methodology and the other in the
absence of data imputation (that is, the observed cases
[OCs]). Analysis for efficacy was performed on a modified
intention-to-treat (ITT) population and per protocol (PP) popu-
lation. The ITT population was defined as those patients who
had received at least one dose of masitinib and who had
undergone at least one post-baseline assessment of efficacy.
The PP population was defined as a subgroup of the ITT pop-
ulation that in addition had presented no major protocol devi-
ations and had completed at least 28 days of treatment
exposure.
Results
Baseline characteristics and participant flow
Between December 2004 and March 2006, a total of 43
patients were enrolled in the study. Participants were ran-
domly assigned to one of two initial treatment groups, receiv-
ing a masitinib dosage of either 3 mg/kg per day (n = 22) or 6
mg/kg per day (n = 21). Of these, 27/43 (63%) patients com-
pleted the study, with 21/43 (49%) patients entering the
study's extension phase (10/43 [23%] patients received treat-
ment for more than 1 year, 8/43 [19%] for more than 2 years
and 3/43 [7%] for more than 3 years). Of the 16 (37%)
patients who withdrew before completion of the 12-week
study period, occurrence of an AE was cited as the primary
cause of discontinuation. Participant baseline characteristics,
disposition and dosing history are presented in Table 1
according to the randomised dose-ranging treatment groups.
Baseline values of several efficacy parameters were higher in
the 6 mg/kg per day group compared with the 3 mg/kg per day
group; for example, DAS28 was, respectively, 7.1 versus 6.1
(P = 0.010), CRP was 62 versus 26 mg/litre (P = 0.029),
swollen joint count was 22.1 versus 15.3 (P = 0.046), previ-
ous anti-TNFα was 67% versus 36% (P = 0.056) and Health
Assessment Questionnaire score was 2.2 versus 1.9 (P =
0.082). Hence, the 6 mg/kg per day initial dosage arm had a
higher baseline of disease severity.
Three patients were excluded from the randomised population
due to lack of efficacy data following baseline; thus, according
to our ITT population definition, the resulting ITT population
was n = 40. This corresponded to 3 and 6 mg/kg per day ran-
domised dose-ranging groups of n = 22 and n = 18, respec-
tively. Four other patients were excluded from the PP
population (n = 36 with n = 18 for each group): one due to a
major protocol violation (that is, treated with prednisone at 20
mg/day before baseline) and three due to insufficient exposure
time (that is, fewer than 28 days).
In regard to analysis of the primary efficacy outcome (that is,
ACR score at week 12), 39/40 (97%) patients had sufficient
post-baseline data available for analysis in the ITT LOCF
group. (The size of this efficacy analysis group differs from that
of the ITT population since, although the missing patient ful-
filled the ITT criteria, he did not possess a sufficiently complete
dataset to permit calculation of the multiparametric ACR
score.) The PP OC efficacy analysis group had sufficient data
available for analysis of 27/36 (75%) patients. Secondary effi-
cacy outcomes were likewise analysed according to the
number of patients possessing sufficient data for evaluation at
12 weeks.
Subgroup analysis of the ITT population with respect to previ-
ous DMARD treatment failure revealed that 20/40 (50%)
patients were unresponsive to anti-TNFα (including 5/40
[12%] patients resistant to one anti-TNFα, 10/40 [25%]
patients resistant to more than one anti-TNFα and 5/40 [12%]
patients intolerant to anti-TNFα). In addition, 33/40 (82%)
patients were unresponsive to MTX. Among them, 18 patients
were unresponsive to both anti-TNFα and MTX. Analyses of
the participant baseline characteristics with respect to previ-
ous treatment failure (data not shown) suggest that, although
the entire population was classified as having 'very active RA',
those patients previously treated with anti-TNFα were suffer-
ing from RA of even greater severity than that of the other
patients.
Safety and tolerability of masitinib
Assessment of safety was performed on all patients who had
received at least one dose of masitinib (n = 43) over the study
duration, including the treatment extension period with a cutoff
date of 31 August 2008. Overall patient exposure to masitinib
was 288 ± 378 days on average, with a median exposure of
91 days and a range of 8 to 1,274 days. The incidence of com-
mon (> 4%) treatment-related AEs according to intensity is
presented in Table 2 for the initial (12-week study period) andAvailable online http://arthritis-research.com/content/11/3/R95
Page 5 of 12
(page number not for citation purposes)
Table 1
Baseline characteristics, overall disposition and dosing history, according to initial dosage
Parameter Masitinib 3 mg/kg per day
(n = 22)
Masitinib 6 mg/kg per day
(n = 18)
Total population
(n = 40)
Demographic (intent-to-treat population)
Age, years
Mean ± SD 54.0 ± 12.2 55.5 ± 9.2 54.7 ± 10.8
Range 27.0–75.0 34.0–69.0 27.0–75.0
Weight, kg
Mean ± SD 67.1 ± 12.8 69.2 ± 20.5 68.1 ± 16.5
Range 49.0–88.0 50.0–136.0 49.0–136.0
Gender
Male 3/22 (13.6%) 6/18 (33.3%) 9/40 (22.5%)
Female 19/22 (86.4%) 12/18 (66.7%) 31/40 (77.5%)
Clinical (intent-to-treat population)
Disease duration in years, mean ± SD 11.8 ± 5.9 10.7 ± 8.1 11.3 ± 6.9
Tender joints, mean ± SD 24.7 ± 11.1 32.2 ± 16.3 28.1 ± 14.0
Swollen joints, mean ± SD 15.3 ± 10.4 22.1 ± 12.0 18.4 ± 11.5
Patient pain assessment, mean ± SD 67.4 ± 19.2 68.6 ± 27.4 67.9 ± 23.0
Patient assessment of DA, mean ± SD 69.4 ± 24.9 73.0 ± 22.9 71.0 ± 23.8
Physician assessment of DA, mean ± SD 66.4 ± 19.5 66.8 ± 18.8 66.6 ± 18.9
HAQ score, mean ± SD 1.9 ± 0.6 2.2 ± 0.5 2.0 ± 0.6
CRP (mg/litre), mean ± SD 26.2 ± 28.4 62.3 ± 57.6 42.3 ± 46.9
DAS28, mean ± SD 6.1 ± 0.8 7.1 ± 1.1 6.5 ± 1.0
DMARD failures (percentage)
Anti-TNFα 8/22 (36.4%) 12/18 (66.7%) 20/40 (50.0%)
Other 14/22 (63.6%) 6/18 (33.3%) 20/40 (50.0%)
Patient disposition (randomised population)
Masitinib 3 mg/kg per day
(n = 22)
Masitinib 6 mg/kg per day
(n = 21)
Total population
(n = 43)
Early study discontinuation 7/22 (31.8%) 9/21 (42.9%) 16/43 (37.2%)
Insufficient therapeutic effect 1/7 (14.3%) 1/9 (11.1%) 2/16 (12.5%)
Protocol violation 0/7 (0.0%) 0/9 (0.0%) 0/16 (0.0%)
Adverse event 6/7 (85.7%) 7/9 (77.8%) 13/16 (81.3%)
Consent withdrawn 0/7 (0.0%) 1/9 (11.1%) 1/16 (6.3%)
End of study without extension 5/22 (22.7%) 1/21 (4.8%) 6/43 (14.0%)
Entered extension phase 10/22 (45.4%) 11/21 (52.3%) 21/43 (48.9%)
Dosing adjustment (intent-to-treat population over 12-week study phase)
Masitinib 3 mg/kg per day
(n = 22)
Masitinib 6 mg/kg per day
(n = 18)
Total population
(n = 40)
No dose adjustment 10/22 (45%) 8/18 (44%) 18/40 (45%)
Increase by 1.5 mg/kg per day 6/22 (27%) 3/18 (17%) 9/40 (23%)
Increase by 3.0 mg/kg per day 2/22 (9%) 5/18 (28%) 7/40 (18%)
Increase by 4.5 mg/kg per day 3/22 (14%) 0/18 (0%) 3/40 (8%)
Othera 1/22 (5%) 2/18 (11%) 3/40 (8%)
Active rheumatoid arthritis patients were randomly assigned to receive masitinib therapy at initial dosing levels of 3.0 or 6.0 mg/kg per day, 
administered per os for 12 weeks. Dose adjustment was permitted depending upon efficacy and safety assessments. Pain and disease activity 
were assessed using an EQ-5D (EuroQoL-5 Dimensions) visual analogue scale. aCombination of dose augmentation and/or diminution. Anti-
TNFα, anti-tumour necrosis factor-alpha; CRP, C-reactive protein; DA, disease activity; DAS28, disease activity score using 28 joint counts; 
DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; SD, standard deviation.Arthritis Research & Therapy    Vol 11 No 3    Tebib et al.
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Table 2
Number (percentage) of subjects with at least one suspected (or not assessable) adverse event, according to intensity
Initial phase
System organ class/preferred terma All (n = 43) Mild Moderate Severe
At least one suspected AEb 40 (93.0%) 29 (67.4%) 27 (62.8%) 9 (20.9%)
Rash-All categories 13 (30.2%) 7 (16.3%) 8 (18.6%) 2 (4.7%)
Oedema-All categories 11 (25.6%) 2 (4.7%) 6 (14.0%) 3 (7.0%)
Nausea 10 (23.3%) 6 (14.0%) 5 (11.6%)
Diarrhoea 8 (18.6%) 5 (11.6%) 2 (4.7%) 1 (2.3%)
Headache 6 (14.0%) 4 (9.3%) 2 (4.7%)
Abdominal pain, upper 5 (11.6%) 4 (9.3%) 1 (2.3%)
Vomiting 5 (11.6%) 1 (2.3%) 4 (9.3%)
Asthenia 5 (11.6%) 4 (9.3%) 1 (2.3%)
Pyrexia 3 (7.0%) 1 (2.3%) 1 (2.3%) 1 (2.3%)
Herpes simplex 3 (7.0%) 2 (4.7%) 1 (2.3%)
Weight decreased 3 (7.0%) 2 (4.7%) 1 (2.3%)
Dyspnoea 3 (7.0%) 1 (2.3%) 1 (2.3%) 1 (2.3%)
Abdominal pain 2 (4.7%) 1 (2.3%) 1 (2.3%)
Dry mouth 2 (4.7%) 1 (2.3%) 1 (2.3%)
Hyperthermia 2 (4.7%) 1 (2.3%) 1 (2.3%)
Gastroenteritis 2 (4.7%) 2 (4.7%)
Blood creatinine increased 2 (4.7%) 1 (2.3%) 1 (2.3%)
Cough 2 (4.7%) 1 (2.3%) 1 (2.3%)
Alopecia 2 (4.7%) 2 (4.7%)
Petechiae 2 (4.7%) 1 (2.3%) 1 (2.3%)
Extension phase
System organ class/preferred term All (n = 21) Mild Moderate Severe
At least one suspected AE 10 (47.6%) 4 (19.0%) 3 (14.3%) 3 (14.3%)
Oedema-All categories 2 (9.5%) 2 (9.5%)
Leukopenia 1 (4.8%) 1 (4.8%)
Vertigo 1 (4.8%) 1 (4.8%)
Aphthous stomatitis 1 (4.8%) 1 (4.8%)
Asthenia 1 (4.8%) 1 (4.8%)
Pyrexia 1 (4.8%) 1 (4.8%)
Liver disorder 1 (4.8%) 1 (4.8%)
Gastroenteritis 1 (4.8%) 1 (4.8%)
Nasopharyngitis 1 (4.8%) 1 (4.8%)
Rhinitis 1 (4.8%) 1 (4.8%)
Neutrophil count decreased 1 (4.8%) 1 (4.8%)
Rheumatoid arthritis 1 (4.8%) 1 (4.8%)
Bronchopneumopathy 1 (4.8%) 1 (4.8%)
Pleural effusion 1 (4.8%) 1 (4.8%)
Eczema 1 (4.8%) 1 (4.8%)
Onychoclasis 1 (4.8%) 1 (4.8%)
Photosensitivity reaction 1 (4.8%) 1 (4.8%)
Table includes those adverse events (AEs) that occurred commonly (that is, in greater than 4% of patients). aMedDRA (medical dictionary for 
regulatory activities) terminology. bAE intensity count is cumulative. AEs were recorded only once (at their start date).Available online http://arthritis-research.com/content/11/3/R95
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extension phases. A total of 40/43 (93%) patients reported at
least one masitinib-related (or not assessable) AE during the
initial phase. In general, AEs were transient in nature and of
mild to moderate intensity; nevertheless, occurrence of AEs
was the main reason that 13/43 (30%) patients discontinued
treatment. In 9/43 (21%) patients, the AEs were severe,
including oedema and rash in 3/43 (7%) and 2/43 (5%)
patients, respectively. One patient presented with
angioedema of moderate intensity (face oedema, rash and
dyspnea without hypotension or any sign of shock). This event
resolved upon masitinib interruption and without specific med-
ications, ruling out any anaphylactic or anaphylactic-like reac-
tion. No changes considered to be of clinical relevance were
observed in regard to physical, haematological or urinalysis
parameters during the initial phase; however, 1/43 (2%)
patient presented with hepatic disorder of increased liver
enzymes (aspartate amino transferase: 122 units/litre, alanine
amino transferase: 188 units/litre and alkaline phosphatase:
635 units/litre) at a dose of 6 mg/kg per day. This episode,
reported as a severe transaminase increase AE, occurred after
14 days of treatment and resolved within 4 weeks of drug with-
drawal, with no reoccurrence following the reintroduction of
treatment. Analysis of AEs with respect to the dose of their
occurrence (data not shown) showed that no clear dose-toxic-
ity relationships exist, with the exception of oedema. The
number of patients experiencing at least one oedema was 11/
43 (26%), with 6/36 (16.7%) for doses of not more than 6.0
mg/kg per day and 5/15 (33.3%) for doses of greater than 6.0
mg/kg per day. Such oedematous episodes typically occurred
4 weeks (median onset time of 28 days) after the first drug
intake or dose increase and abated within an average of 16
days. Four (9%) patients reported nonfatal SAEs of severe
intensity which were suspected to be related to masitinib (or
not assessable) and which consisted of skin rash, pleural effu-
sion, pneumonia and RA flare-up. Only one of those SAEs
(pleural effusion) resulted in patient withdrawal. All of these
patients recovered without sequelae, and no deaths occurred
during this study.
For patients entering the extension phase (n = 21), a clear
decrease in the occurrence of AEs as well as a reduction in
severity were evident. Overall, 10/21 (48%) patients reported
at least one masitinib-related (or not assessable) AE; these
AEs were of mild, moderate or severe intensity in 4/21 (19%),
3/21 (14%) and 3/21 (14%) patients, respectively. Specifi-
cally, no incidence of skin rash, nausea, vomiting or diarrhoea
was reported after week 12, and occurrence of oedema
decreased more than 60%.
Clinical efficacy of masitinib
Evaluation of the primary efficacy endpoint ACR and the sec-
ondary endpoints of ACRn, DAS28 and CRP improvement is
presented in Table 3 according to the ITT LOCF and PP OC
analysis groups. Treatment with masitinib significantly
i m p r o v e d  t h e  s e v e r i t y  o f  a c t i v e  R A :  a t  w e e k  1 2 ,  A C R 2 0 ,
ACR50 and ACR70 were achieved by 15/27 (55.6%), 9/27
(33.3%) and 3/27 (11.1%) patients, respectively, in the PP
OC group. The corresponding numbers in the ITT LOCF
group were 21/39 (53.8%), 10/39 (25.6%) and 3/39 (7.7%).
These results are presented as the cumulative number of
patients reaching each ACR level, with performance observed
to be similar between efficacy analysis groups; the slightly
lower response in ITT LOCF was attributable to the fact that
imputed data were typically associated with patient withdrawal
and, therefore, a lower treatment exposure. Considerable
improvement was also observed in the ACRn analysis, the PP
OC and ITT LOCF analysis groups achieving an improvement
of 31.6 and 23.0 units, respectively, at week 12. With respect
to DAS28 values, the PP OC and ITT LOCF populations
exhibited an absolute change of 2.0 and 1.7 units, respec-
tively, from a baseline of 6.5 units, representing an improve-
ment in DAS28 classification from 'very active RA' to
'moderate RA'. In regard to the number of patients with a
DAS28 of less than 2.6 (classified as disease remission), two
patients from the ITT LOCF population's MTX subgroup exhib-
ited this improvement but none from the anti-TNFα subgroup
did. Finally, approximately 50% of patients experienced a sig-
nificant reduction (> 50%) in their CRP levels, signifying a
decrease in their inflammation.
The pattern of masitinib efficacy appears to be independent of
previous treatment failure, with approximately 50% of patients
achieving the ARC20 and ΔCRP greater than 50% response
criteria regardless of previous treatment (Table 3); that is, mas-
itinib is equally effective in patients for whom previous treat-
ment with anti-TNFα or MTX has been inadequate. Preliminary
results from the extension phase are of major interest since
they show the observed improvement to be consistently main-
tained over a duration of more than 84 weeks, demonstrating
masitinib's sustainability (Table 4). In regard to the DAS28
extension phase data after 1 year of treatment (60 weeks), an
increasing number of patients were achieving DAS28 values
of not more than 3.2 or less than 2.6, signifying inactive RA or
an increased likelihood of being in remission. Furthermore,
over this time, two patients achieved up to 90% improvement
(ACR90). Taken together, this suggests that further therapeu-
tic gains could possibly be achieved given longer exposure
times.
Dose analysis
An analysis of time to first response according to initial dosage
is presented in Table 5. This analysis extends to the extension
phase for a total assessment period of approximately 32
weeks. Patients randomly assigned to the 6 mg/kg per day
dosing group achieved a response faster than those assigned
to the 3 mg/kg per day (ACR20: median of 29 versus 56 days
[P  = 0.231]; ACR50: 72.5 versus 84 days [P  = 0.771],
respectively); however, these differences were not statistically
significant (P  < 0.05). In cases of insufficient treatment
response, dose adjustment was permitted at weeks 4 and 8;Arthritis Research & Therapy    Vol 11 No 3    Tebib et al.
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hence, the dose at time of first response was also analysed.
Results reveal that approximately 65% and 73% of those
patients achieving ACR20 or ACR50 scores, respectively, did
so at a dosage of not more than 6 mg/kg per day. Moreover,
this dosage corresponded to the highest response rate (5/15,
33.3%) for the ACR50 threshold. For those patients randomly
assigned to the 3 mg/kg per day dosing group, 12/22 (55%)
received dose augmentation at weeks 4 or 8 due to insufficient
response. Of these, 7/12 (58%) patients experienced an
improved response within the initial 12-week phase whereas
5/12 (42%) patients were nonresponders, having failed to
reach the ACR20 threshold.
Discussion
Although the incidence of AEs was high in the study popula-
tion as a whole (95%), the majority of these were mild or mod-
erate in severity, transitory in nature and resolved
spontaneously or upon temporary treatment interruption.
Moreover, because this was the first study of masitinib as
treatment in a nononcologic pathology, the increased inci-
dence of dermatological events typically associated with this
therapeutic class [20] was understandably treated with great
caution by patients and investigators alike. This may in part
explain the relatively high dropout rate of patients. Of those
who withdrew from the study because of AEs prior to week 12
Table 3
Summary of efficacy outcomes at week 12 with subgroup analysis according to previous treatment failure
Parameter PP OCs ITT LOCF
All patients Resistance to
anti-TNFα
Resistance to MTX All patients Resistance to
anti-TNFα
Resistance to
MTX
ACRa (n = 27) (n = 14) (n = 23) (n = 39) (n = 19) (n = 32)
ACR20 15/27 (55.6%) 8/14 (57.1%) 14/23 (60.9%) 21/39 (53.8%) 10/19 (52.6%) 17/32 (53.1%)
ACR50 9/27 (33.3%) 4/14 (28.6%) 9/23 (39.1%) 10/39 (25.6%) 4/19 (21.1%) 9/32 (28.1%)
ACR70 3/27 (11.1%) 1/14 (7.1%) 3/23 (13.0%) 3/39 (7.7%) 1/19 (5.3%) 3/32 (9.4%)
ACRn
Mean ± SD 31.6 ± 33.5 28.1 ± 32.1 36.6 ± 31.6 23.0 ± 37.5 18.7 ± 36.8 24.1 ± 38.8
Median 42.9 44.3 46.9 25.7 20.6 32.7
Range -40.0–87.5 -40.0–72.2 -40.0–87.5 -62.5–87.5 -62.5–72.2 -62.5–87.5
CRP (n = 28) (n = 14) (n = 23) (n = 35) (n = 17) (n = 29)
Improvement > 50% 14/28 (50.0%) 7/14 (50.0%) 12/23 (52.2%) 19/35 (54.3%) 9/17 (52.9%) 16/29 (55.2%)
25% < improvement ≤ 50% 3/28 (10.7%) 1/14 (7.1%) 2/23 (8.7%) 4/35 (11.4%) 2/17 (11.8%) 3/29 (10.3%)
0% ≤ improvement ≤ 25% 5/28 (17.9%) 1/14 (7.1%) 3/23 (13.0%) 5/35 (14.3%) 1/17 (5.9%) 3/29 (10.3%)
Stability 3/28 (11%) 3/14 (21%) 3/23 (13%) 3/35 (9%) 3/17 (18%) 3/29 (10%)
Deterioration 3/28 (11%) 2/14 (14%) 3/23 (13%) 4/35 (11%) 2/17 (12%) 4/29 (14%)
DAS28 (n = 24) (n = 13) (n = 20) (n = 34) (n = 18) (n = 28)
Mean ± SD 4.6 ± 1.3 5.1 ± 1.2 4.6 ± 1.4 4.8 ± 1.5 5.2 ± 1.1 4.8 ± 1.5
ΔDAS28 2.0 1.8 2.1 1.7 1.7 1.8
Range 0.5–7.0 3.3–7.0 0.5–7.0 0.5–7.0 3.3–7.0 0.5–7.0
DAS28 < 2.6 1/24 (4.2%) 0/28 (0%) 1/20 (5.0%) 2/34 (5.9%) 0/18 (0%) 2/28 (7.1%)
DAS28 ≤ 3.2 1/24 (4.2%) 0/28 (0%) 1/20 (5.0%) 2/34 (5.9%) 0/18 (0%) 2/28 (7.1%)
aPrimary efficacy outcome. American College of Rheumatology (ACR) results are presented as the cumulative number of patients reaching each 
ACR level. Population sizes could vary with respect to an efficacy endpoint due to the fact that, for some patients, all efficacy data under treatment 
were missing (no data imputation was possible in this case). ACR20/50/70, American College of Rheumatology 20%/50%/70% improvement 
criteria; ACRn, index of improvement in rheumatoid arthritis; anti-TNFα, anti-tumour necrosis factor-alpha; CRP, C-reactive protein; DAS28, 
disease activity score using 28 joint counts; ΔDAS28, the change in disease activity score using 28 joint counts from baseline; ITT, intention-to-
treat; LOCF, last observation carried forward; MTX, methotrexate; OC, observed case; PP, per protocol population; SD, standard deviation.Available online http://arthritis-research.com/content/11/3/R95
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(n = 13), 9/13 (69%) patients had experienced AEs of a mild
or moderate intensity, which could feasibly have been man-
aged without permanent interruption of treatment. In general,
AEs occurred early during the course of treatment, which is
consistent with the known safety profile of TK inhibitors [21].
This trend is clearly evident when comparing safety data from
the initial and extension phases, the implication being that,
although masitinib is not completely free from side effects, the
majority of these are over following 12 weeks of treatment,
with good tolerance experienced thereafter during any long-
term treatment regimen. During the initial 12 weeks, the most
common AEs were rashes, oedema, nausea and diarrhoea.
Cutaneous rash may potentially be linked to the action of mas-
itinib on MCs, inducing MC apoptosis with a subsequent
release of various mediators (for example, histamine, prostag-
landins or cytokines) that are responsible for rash. This apop-
tosis seems to happen only once. The time necessary for the
released mediators to reach the reaction site and accumulate
to a certain concentration in the skin might explain why such
events typically manifest themselves between the second and
third weeks of treatment. Diarrhoea may also be linked to the
pharmacological activity of masitinib on MCs in the intestine or
through direct action on Cajals cells of the intestine, which
also express the c-KIT receptor. Oedema, mainly palpebral
and face oedema, is thought to be linked to the activity of mas-
itinib on PDGFR, a TK receptor involved in the vasculatory
pressure of tissues, especially in the periorbital region sensible
to low pressure.
Table 4
Efficacy outcomesa from the extension phase of the study: weeks 12 to 82 (intention-to-treat population)
Parameter W12 W24 W36 W48 W60 W72 W84
ACR, number (percentage) of patients n = 27 n = 7 n = 9 n = 8 n = 8 n = 9 n = 8
ACR20b 15 (56%) 6 (86%) 7 (78%) 5 (63%) 6 (75%) 6 (67%) 7 (88%)
ACR50b 9 (33%) 2 (27%) 4 (44%) 3 (38%) 6 (75%) 3 (33%) 5 (63%)
ACR70 3 (11%) 1 (14%) 2 (22%) 1 (13%) 3 (38%) 2 (22%) 2 (25%)
ACR90 0 (0%) 0 (0%) 1 (11%) 0 (0%) 2 (25%) 1 (11%) 1 (13%)
ACRn n = 27 n = 7 n = 9 n = 8 n = 8 n = 9 n = 8
Mean ± SD 31.6 ± 33.5 36.0 ± 29.0 45.9 ± 32.3 30.9 ± 36.7 58.3 ± 31.4 35.6 ± 41.3 50.9 ± 38.0
Median 42.9 40.7 45.5 40.0 64.9 39.7 55.0
Range -40.0–87.5 -16.7–73.0 -3.8–93.3 -20.0–70.9 10.0–93.3 -27.8–97.4 -17.6–98.8
CRP, number (percentage) of patients n = 28 n = 7 n = 12 n = 9 n = 7 n = 9 n = 8
Improvement > 50% 14 (50%) 5 (71%) 9 (75%) 6 (67%) 3 (43%) 6 (68%) 5 (63%)
25% < improvement ≤ 50% 3 (11%) 0 (0%) 1 (8%) 0 (0%) 3 (43%) 1 (11%) 1 (13%)
0% < improvement ≤ 25% 5 (18%) 1 (14%) 1 (8%) 1 (11%) 1 (14%) 1 (11%) 1 (13%)
Stable 3 (11%) 1 (14%) 1 (8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Deterioration 3 (11%) 0 (0%) 0 (0%) 2 (22%) 0 (0%) 1 (11%) 1 (13%)
DAS28 n = 24 n = 4 n = 5 n = 6 n = 7 n = 7 n = 4
Mean ± SD 4.6 ± 1.3 5.2 ± 1.7 4.4 ± 1.9 4.7 ± 2.1 3.3 ± 1.5 3.5 ± 1.5 3.1 ± 1.6
Median 4.4 4.9 4.1 4.4 2.6 3.0 2.5
Range 0.5–7.0 3.6–7.5 2.3–7.5 2.7–8.7 1.7–5.3 1.6–6.1 1.9–5.5
DAS28 < 2.6, number (percentage) of 
patients
1 (4%) 0 (0%) 1 (20%) 0 (0%) 4 (57%) 1 (14%) 2 (50%)
DAS28 ≤ 3.2, number (percentage) of 
patients
1 (4%) 0 (0%) 1 (20%) 2 (33%) 4 (57%) 4 (57%) 3 (75%)
aResults from extension phase are preliminary. bPrimary efficacy outcome. American College of Rheumatology (ACR) results are presented as the 
cumulative number of patients reaching each ACR level. ACR20/50/70/90, American College of Rheumatology 20%/50%/70%/90% 
improvement criteria; ACRn, index of improvement in rheumatoid arthritis; DAS28, disease activity score using 28 joint counts; CRP, C-reactive 
protein; SD, standard deviation; W, week.Arthritis Research & Therapy    Vol 11 No 3    Tebib et al.
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Overall, the safety profile of masitinib for long-term treatment
would appear favourable, especially when considering con-
cerns of cardiotoxicity and genotoxicity. For example, imatinib
mesylate (Gleevec, STI571; Novartis, Basel, Switzerland) is
cardiotoxic due to its strong inhibition of the Abelson kinase
(ABL) [22,23], making its long-term use questionable for treat-
ment of active RA. Masitinib, in contrast, is a weak inhibitor of
BCR-ABL (and is also either an inactive or a weak inhibitor of
other known cardiotoxic kinases such as Src and vascular
endothelial growth factor receptor [VEGFR]), implying that
masitinib may exhibit a better safety profile than other TK inhib-
itors, particularly on cardiac functions (P. Dubreuil and col-
leagues, manuscript submitted). Preclinical studies have also
shown that masitinib is not genotoxic.
The performance of masitinib, with respect to the primary end-
point ACR scores, compares favourably to other biological
DMARDs, including rituximab, abatacept and adalimumab
[24-27]. Moreover, due to a lack of dosage increase in the
event of insufficient response without toxicity (a protocol devi-
ation), some patients may not have benefited from an optimal
masitinib dose with a consequent reduction in efficacy results.
Observed clinical improvement was supported by laboratory
evidence of reduced inflammation in the form of a significant
and sustainable decrease in CRP level for approximately half
the study population. This result is important since, in the
absence of a control group, it serves as proof that the
observed improvements are attributable to the treatment. The
results from other secondary endpoints (ACRn and DAS28)
provide additional evidence of efficacy, with consistent pat-
terns to the primary endpoint regarding sustainability and inde-
pendence from previous treatment failure.
Dose-response analyses tentatively indicate that a dose level
of 6 mg/kg per day is the most potent, although inequality of
baseline clinical parameters between dose groups may be a
confounding influence. Hence, no definite conclusion on the
optimal initial dosing level can be reached. In regard to tolera-
bility, the majority of severe AEs were associated with doses
of at least 7.5 mg/kg per day. Thus, utilisation of not more than
6 mg/kg per day would likely reduce the occurrence of severe
AEs, in particular those associated with oedema.
Conclusions
Within the limitations of an uncontrolled phase 2a trial, this
study has indicated that masitinib is a generally well-tolerated
(especially after the initial 12 weeks) and effective treatment
for DMARD-refractory active RA. Given the selective antimas-
tocyte mechanism of action of masitinib, the results of this
study help to further establish the critical role of MCs in the
pathogenesis of active RA. More specifically, this study sup-
ports the viability of exploiting the SCF/c-KIT pathway as a
therapeutic target. There is sufficient compelling evidence to
proceed to phase 2b/3 randomised clinical trials to confirm
and further characterise these findings.
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